Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: mc who wrote (11006)	7/9/1998 6:23:00 PM
From: VLAD	Read Replies (4) \| Respond to of 23519

Here are some calculations on product sales both domestic and international: Domestic: Income from domestic sales in Q2 was only 6.2 million compared to 24.5 million in Q1. So the Viagra effect ate no less than 75% of domestic net income. This is not good but it was expected and between the media hype and every older guy wanting to give Viagra a spin it is the worst part of the current situation. International: Income up from 2 to 9.8 million from Q1 to Q2 which represents a 490% increase. With new countries coming on line each month I believe that Q3 international income will easily surpass 20 million. Also, don't forget milestone payments in Q3--Canada for sure at 2 million and an additional 10 million if Spain, Germany, France, and Italy give approval. The key at this point is for Vivus to cut a domestic deal with J&J or Astra/Merck ASAP since domestic sales have such a high profit margin. With increased international sales, no sales force expense and a strong domestic partner, Vivus should be able to manage a profit of at least 20 if not over 30 cents in Q3.